Showing results (291-300 of 309) with videos related to
Sort By:
Pageof 31
Plos Pathogens|June 2, 2017
Mycobacterium tuberculosis subverts negative regulatory pathways in human macrophages to drive immunopathologyPatience T Brace, Liku B Tezera, Magdalena K Bielecka, et al.Blood Advances|March 22, 2022
Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variationKatie E Joyce, Ebun Onabanjo, Sheila Brownlow, et al.Artificial Organs|July 9, 2026
National Practice Patterns of VA ECMO and Left Ventricular Mechanical Unloading for Cardiogenic ShockDustin M Anderson-Bell, Morgan M Millar, Rachel R Codden, et al.Cancer Medicine|October 24, 2024
Tattoos and Risk of Hematologic Cancer: A Population-Based Case-Control Study in UtahRachel D McCarty, Britton Trabert, David Kriebel, et al.Plos One|June 27, 2017
In vitro and in vivo effects of kisspeptin antagonists p234, p271, p354, and p356 on GPR54 activationC H J Albers-Wolthers, J de Gier, M Walen, et al.American Journal of Epidemiology|January 29, 2019
Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based StudiesMorgan M Millar, Anita Y Kinney, Nicola J Camp, et al.JAMA Network Open|October 4, 2021
Differences in Breast and Colorectal Cancer Screening Adherence Among Women Residing in Urban and Rural Communities in the United StatesSanjay Shete, Yangyang Deng, Jackilen Shannon, et al.Orphanet Journal of Rare Diseases|August 30, 2019
Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasiaC L Shovlin, C M Millar, F Droege, et al.Journal of the American Heart Association|May 19, 2021
Inequities in Hypertension Control in the United States Exposed and Exacerbated by COVID-19 and the Role of Home Blood Pressure and Virtual Health Care During and After the COVID-19 PandemicAdam P Bress, Jordana B Cohen, David Edmund Anstey, et al.Research and Practice in Thrombosis and Haemostasis|May 1, 2026
Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial resultsAndrew D Leavitt, Johnny Mahlangu, Priyanka Raheja, et al.Pageof 31